Quick Answer
ANI PHARMACEUTICALS INC reported Net Income Loss of $78.34 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +522.9% in Net Income Loss from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $35.4 thousand | Q3 2012: -$377.3 thousand | Q1 2013: $260.0 thousand | Q2 2013: -$4.58 million | Q3 2013: $1.19 million | Q1 2014: $3.36 million | Q2 2014: -$2.36 million | Q3 2014: $6.75 million | Q1 2015: $4.37 million | Q2 2015: $3.57 million | Q3 2015: $4.56 million | Q1 2016: $1.35 million | Q2 2016: $1.13 million | Q3 2016: $2.54 million | Q1 2017: $1.15 million | Q2 2017: $2.68 million | Q3 2017: $4.72 million | Q1 2018: $2.25 million | Q2 2018: $2.78 million | Q3 2018: $5.04 million | Q1 2019: $449.0 thousand | Q2 2019: $6.59 million | Q3 2019: $3.90 million | Q4 2019: -$4.84 million | Q1 2020: -$7.01 million | Q2 2020: -$12.34 million | Q3 2020: $434.0 thousand | Q4 2020: -$3.64 million | Q1 2021: $86.0 thousand | Q2 2021: -$14.11 million | Q3 2021: -$4.45 million | Q1 2022: -$20.13 million | Q2 2022: -$14.92 million | Q3 2022: -$8.60 million | Q1 2023: $1.44 million | Q2 2023: $6.25 million | Q3 2023: $9.94 million | Q1 2024: $18.21 million | Q2 2024: -$2.29 million | Q3 2024: -$24.17 million | Q1 2025: $15.68 million | Q2 2025: $8.55 million | Q3 2025: $26.62 million.
- Over the full 14 years of available data (2012 to 2025), ANI PHARMACEUTICALS INC's Net Income Loss has grown by 5,301.7%.
- Historical annual values: Fiscal year 2025: $78.34 million | Fiscal year 2024: -$18.52 million | Fiscal year 2023: $18.78 million | Fiscal year 2022: -$47.90 million | Fiscal year 2021: -$42.60 million | Fiscal year 2020: -$22.55 million | Fiscal year 2019: $6.09 million | Fiscal year 2018: $15.49 million | Fiscal year 2017: -$1.08 million | Fiscal year 2016: $3.93 million | Fiscal year 2015: $15.38 million | Fiscal year 2014: $28.75 million | Fiscal year 2013: $301.0 thousand | Fiscal year 2012: -$1.51 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: